Literature DB >> 16113839

Coagulation factor XIII-A. A flow cytometric intracellular marker in the classification of acute myeloid leukemias.

János Kappelmayer1, Agnes Simon, Eva Katona, Attila Szanto, László Nagy, Attila Kiss, Csongor Kiss, László Muszbek.   

Abstract

The association of coagulation factors with leukocytes have been demonstrated in several previous studies. This study was designed to study the sensitivity and specificity of factor XIII subunit A (FXIII-A) labelling in cultured myeloblastic and monoblastic cell lines and to investigate the intracytoplasmic expression of FXIII-A in de novo acute myeloid leukemia (AML) samples. Myeloblastic and a monoblastic cell lines were cultured and investigated for lineage specific maturation markers and FXIII-A expression. Furthermore, FXIII-A expression was investigated in 12 normal samples (7 bone marrow and 5 peripheral blood), 86 de novo AML samples and 6 chronic myelomonocytic leukemia (CMML) samples. In the monoblastic MonoMac6 cell line the appearance of FXIII-A preceded that of CD14 while it remained negative in the myeloblastic PLB-985 cell line throughout its maturation period. Among the AML samples the average frequency of FXIII-A positive cells in myeloblastic leukemia samples was below 10%, while in M4 and M5AML samples it was above 50% and was significantly higher than the generally used CD14 marker (p < 0.0001). In the AML M4 and M5 cases, FXIII-A proved sensitive for the identification of monoblasts. FXIII-A can be considered as a reliable intracytoplasmic marker for the monocytic and megakaryocytic series and its presence is highly predictive for mono- and megakaryocytic AML and for CMML.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113839     DOI: 10.1160/TH05-03-0206

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Expression of Coagulation Factor XIII Subunit A Correlates with Outcome in Childhood Acute Lymphoblastic Leukemia.

Authors:  Bettina Kárai; Zsuzsanna Hevessy; Eszter Szánthó; László Csáthy; Anikó Ujfalusi; Katalin Gyurina; István Szegedi; János Kappelmayer; Csongor Kiss
Journal:  Pathol Oncol Res       Date:  2017-05-18       Impact factor: 3.201

Review 2.  Advances of Coagulation Factor XIII.

Authors:  Da-Yu Shi; Shu-Jie Wang
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

3.  Coagulation FXIII-A Protein Expression Defines Three Novel Sub-populations in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia Characterized by Distinct Gene Expression Signatures.

Authors:  Katalin Gyurina; Bettina Kárai; Anikó Ujfalusi; Zsuzsanna Hevessy; Gábor Barna; Pál Jáksó; Gyöngyi Pálfi-Mészáros; Szilárd Póliska; Beáta Scholtz; János Kappelmayer; Gábor Zahuczky; Csongor Kiss
Journal:  Front Oncol       Date:  2019-10-25       Impact factor: 6.244

4.  Coagulation Factor XIII Subunit A Is a Biomarker for Curative Effects and Prognosis in Malignant Solid Tumors, Especially Non-small Cell Lung Cancer.

Authors:  Yujiao Luo; Bin Li; Ji Li; Yang Zhang; Mingyang Deng; Chunhong Hu; Wenzhe Yan; Zhiguang Zhou; Guangsen Zhang
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

5.  [Variation of expression level and activity of coagulation factor ⅩⅢ in acute myeloid leukemia patients].

Authors:  D Y Shi; S J Wang; Y Q Zhao; L K Fan; W Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-10-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.